Navigation Links
Cleveland Clinic selected to participate in National MDS Clinical Research Consortium
Date:6/7/2012

Thursday, June 7, 2012, Cleveland: Taussig Cancer Institute at Cleveland Clinic will participate in an unprecedented, six-institution consortium designed to conduct clinical trials and research to improve outcomes for patients with myelodysplastic syndrome (MDS). Known as the MDS Clinical Research Consortium, the five-year, $16 million initiative is sponsored by the Aplastic Anemia & MDS International Foundation and supported by the Edward P. Evans Foundation.

This is the first privately funded MDS research consortium in the U.S. Mikkael Sekeres, M.D., M.S., Director of Taussig Cancer Institute's Leukemia Program, will co-chair the Consortium with Guillermo Garcia-Manero, M.D. of MD Anderson Cancer Center. The Consortium will fill a major gap in MDS-related clinical research by providing a new "critical mass" of dedicated institutions to support the evaluation of promising new therapies, epidemiological studies, and translational studies leading to new treatments and classifications for these diseases. It will also sponsor a yearly, dedicated MDS fellowship slot at each institution.

Centralized clinical operations (data collection and management, biostatistics, clinical trial accrual and supervision of research protocols) will be housed at Taussig Cancer Institute. The Consortium will be administered by the Aplastic Anemia & MDS International Foundation.

"This Consortium is the first clinical research network created to support the infrastructure that makes MDS clinical research happen by enabling the collaboration of the leading MDS centers is the U.S.," said Dr. Sekeres.

The other five participating institutions include Dana Farber Cancer Institute; MD Anderson Cancer Center; H. Lee Moffitt Cancer Center and Research Institute; Weill Medical College of Cornell University; and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

"One of the greatest challenges in research of rare diseases like MDS is having enough patients to conduct meaningful clinical trials. No single center can do it alone. This uniquely collaborative effort overcomes that barrier," said John Huber, Executive Director of the Aplastic Anemia & MDS International Foundation. "To have these six leading MDS research centers working together in this way is unprecedented."

Programs selected as part of the Consortium are based at U.S. academic medical centers that serve a high volume of MDS patients; that maintain a current and historical patient data base; and that have a current and retrospective MDS patient cohort of sufficient size to have a very significant track record of participation in MDS-related clinical trials.

MDS is a cancer of hematopoietic bone marrow stem cells akin to leukemia that inhibits the body's ability to produce healthy blood cells. It principally affects adults over the age of 60 years, and can be treated with chemotherapy, growth factor, or immuonomodulatory therapies. At present, the only cure is a bone marrow transplant.


'/>"/>
Contact: Joe Milicia
milicij2@ccf.org
216-312-0591
Cleveland Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic, youth mental health experts, publish new guidelines to treat childhood aggression
2. Mayo Clinic Alzheimers researcher honored twice in a month
3. Mayo Clinic urologists present findings at American Urological Association Annual Meeting
4. Canada should significantly increase its funding of randomized clinical trials
5. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
6. Mayo Clinic: Standard heart disease risk tools underrate danger in rheumatoid arthritis
7. Experts call for clinical trials to test non-skeletal benefits of vitamin D
8. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
9. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
10. Automated insulin dosage titration system demonstrates positive clinical study results
11. Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... Atlanta, GA (PRWEB) , ... May 31, 2016 ... ... Contact Center Solutions , today announced it has been included by Gartner, ... 2016 report mentions a wide range of Contact Center Infrastructure technologies, some of ...
(Date:5/31/2016)... ... May 31, 2016 , ... Splashtop Inc., the worldwide leader ... with e-Jan Networks Co., the leading provider of secure mobile remote access solution ... Networks’s leading CACHATTO remote access solution. Splashtop for CACHATTO will be ...
(Date:5/31/2016)... ... May 31, 2016 , ... St. Joseph Medical Center (SJMC) ... exchange, which enables physicians at SJMC’s two hospital campuses, downtown and in the ... in the exchange. SJMC’s membership in the health information exchange underscores the hospital’s ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Twenty years ago ... experience, rather than trying to silence the voices they hear. But this approach has ... itself. , The method has steadily gained credibility and now is used around the ...
(Date:5/31/2016)... ... 31, 2016 , ... The University of Tennessee Medical Center ... the latest in Clinical Patient Pod (CPP) technologies provided through Jvion’s ... into the clinical workflow. These insights are empowering the more than 30 case ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... May 31, 2016   Plexus Technology Group, ... anesthesia information management systems (AIMS), is pleased to ... as Vice President of Technology. In this new ... aspects of the company,s technological development. He will ... to determine the expansion of new products, product ...
(Date:5/31/2016)... , May 31, 2016 ... market is progressing at a CAGR of 10.6% within ... was valued at US$0.46 bn in 2013. Owing to ... expected to reach US$0.88 bn by the end of ... derived from the market,s holistic representation in a research ...
(Date:5/31/2016)... , May 31, 2016 ... the initiation of a first-in-human clinical trial of its ... molecule - S101 is currently being developed for the ... study is designed to evaluate the safety and tolerability ... at several sites across the United States ...
Breaking Medicine Technology: